CYP11B1 (P15538) variants and mutations
CYP11B1 (also known as P15538) is a human protein-coding gene encoding a cytochrome P450 11B1, mitochondrial protein. It catalyzes the final step of cortisol synthesis and also contributes to adrenal steroid metabolism. Biallelic loss-of-function variants cause 11-beta-hydroxylase-deficient congenital adrenal hyperplasia, characterized by cortisol deficiency, androgen excess, and frequently hypertension. This analysis covers 1,063 CYP11B1 variants and mutations. Of these, 78% have computational variant effect predictions. Disease context includes congenital adrenal hyperplasia due to 11-beta-hydroxylase deficiency, glucocorticoid-remediable aldosteronism, and congenital adrenal hyperplasia. Example CYP11B1 variants include M1L, A2T, and L3F.
Variant analysis overview
- Gene: CYP11B1
- Protein: P15538
- UniProt accession: P15538
- Organism: Homo sapiens
- Variants analyzed: 1063
- Variant scope: all variants
- Completed: 2026-08-21
Variant and mutation evidence
- Variant composition: 845 unspecified-consequence records; 1 stop retained variant; 103 missense variants; 85 synonymous variants; 13 frameshift variants; 6 stop-gained variants; 4 splice-region variants; 2 in-frame insertions; 3 in-frame deletions; 3 substitution
- Prediction scores: 832 variants have prediction scores (78% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: congenital adrenal hyperplasia due to 11-beta-hydroxylase deficiency, glucocorticoid-remediable aldosteronism, congenital adrenal hyperplasia, Cushing syndrome, adrenal gland disorder, adrenal cortex carcinoma, ACTH-dependent Cushing syndrome, neoplasm, adrenal gland hyperfunction, adrenal cortex neoplasm, depressive disorder, ACTH Syndrome, Ectopic.
Protein structure and variant hotspots
- Protein features: 1 binding sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, MaveDB, LitVar.
Notable CYP11B1 variants
Examples include M1L, A2T, L3F, R4K, R4M, A5E, A5S, K6Q. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- M1L (p.Met1Leu), rs780624046, []
- A2T (p.Ala2Thr), rs746696910, ClinGen CA4905744, ClinVar RCV002645652, ExAC rs746696910, REVEL 0.06, CADD 9.04, Uncertain significance, not provided
- L3F (p.Leu3Phe), ExAC rs777199047, gnomAD rs777199047, REVEL 0.09, CADD 0.20
- R4K (p.Arg4Lys), rs748062304, NCI-TCGA Cosmic COSV5282, NCI-TCGA Cosmic COSV9945, cosmic curated COSV99454, REVEL 0.23, AlphaMissense 0.29, Variant assessed as somatic; moderate impact.
- R4M (p.Arg4Met), rs748062304, NCI-TCGA Cosmic COSV5282, cosmic curated COSV52829, NCI-TCGA Cosmic COSV9945, AlphaMissense 0.29, MetaLR 0.55, Variant assessed as somatic; moderate impact.
- A5E (p.Ala5Glu), NCI-TCGA Cosmic COSV5282, cosmic curated COSV52829, REVEL 0.34, CADD 11.20, Variant assessed as somatic; moderate impact.
- A5S (p.Ala5Ser), TOPMed rs1817090309, REVEL 0.14, CADD 5.15, Uncertain significance, not provided
- K6Q (p.Lys6Gln), gnomAD rs1157744449, REVEL 0.09, CADD 8.17, Uncertain significance, Glucocorticoid-remediable aldosteronism; Deficiency of steroid 11-beta-monooxyge
- K6K (p.Lys6Lys), rs762759122, gnomAD 8-142875378-C-T, CADD 2.73
- K6N (p.Lys6Asn), gnomAD 8-142875378-C-A, CADD 2.63
- K6R (p.Lys6Arg), gnomAD 8-142875380-TC-T, CADD 2.88
- A7T (p.Ala7Thr), rs1349746694, TOPMed rs1349746694, gnomAD rs1349746694, REVEL 0.08, CADD 4.35, Variant assessed as somatic; moderate impact.
- E8* (p.Glu8Ter), NCI-TCGA TCGA novel, Variant assessed as somatic; high impact.
- E8D (p.Glu8Asp), cosmic curated COSV52825, TOPMed rs1423374041, Likely benign
- E8K (p.Glu8Lys), Ensembl rs1817090129
- V9A (p.Val9Ala), rs1554653718, ClinGen CA372397485, ClinVar RCV000517023, ClinVar RCV002481671, REVEL 0.16, CADD 6.84, Uncertain significance, Deficiency of steroid 11-beta-monooxygenase; Glucocorticoid-remediable aldostero
- V9M (p.Val9Met), ESP rs150163594, TOPMed rs150163594, gnomAD rs150163594, REVEL 0.09, CADD 7.39
- C10G (p.Cys10Gly), ExAC rs778976411, TOPMed rs778976411, gnomAD rs778976411, REVEL 0.18, CADD 4.87, Uncertain significance, Glucocorticoid-remediable aldosteronism; Deficiency of steroid 11-beta-monooxyge
- C10R (p.Cys10Arg), ExAC rs778976411, TOPMed rs778976411, gnomAD rs778976411, REVEL 0.20, CADD 1.81, Uncertain significance, Glucocorticoid-remediable aldosteronism; Deficiency of steroid 11-beta-monooxyge
- C10Y (p.Cys10Tyr), rs6405, ClinGen CA4905738, ClinVar RCV001358047, ClinVar RCV002493832, REVEL 0.24, CADD 15.90, Likely benign, Glucocorticoid-remediable aldosteronism; Deficiency of steroid 11-beta-monooxyge
- M11T (p.Met11Thr), TOPMed rs1817089502, gnomAD rs1817089502, REVEL 0.16, CADD 0.31
- M11V (p.Met11Val), Ensembl rs747434849, REVEL 0.19, CADD 0.52
- P14L (p.Pro14Leu), gnomAD rs1304483373, REVEL 0.25, CADD 22.20
- P14R (p.Pro14Arg), NCI-TCGA Cosmic COSV5282, cosmic curated COSV52825, Variant assessed as somatic; moderate impact.
- P14S (p.Pro14Ser), ExAC rs779731828, TOPMed rs779731828, gnomAD rs779731828, REVEL 0.11, CADD 0.52, Uncertain significance, Inborn genetic diseases
- W15* (p.Trp15Ter), rs1554653714, ClinGen CA372397447, ClinVar RCV000674379, ClinVar RCV001855607, Pathogenic
- S17C (p.Ser17Cys), 1000Genomes rs142591816, ESP rs142591816, ExAC rs142591816, TOPMed rs142591816, Likely benign
- S17F (p.Ser17Phe), rs142591816, ClinGen CA4905733, cosmic curated COSV99455, ClinVar RCV000516509, REVEL 0.27, CADD 15.70, Conflicting interpretations, not specified; not provided
- S17P (p.Ser17Pro), ExAC rs751833268, TOPMed rs751833268, gnomAD rs751833268, REVEL 0.44, CADD 14.80
- S17S (p.Ser17Ser), gnomAD 8-142875333-A-G, CADD 2.48
- S17T (p.Ser17Thr), rs1195144979, gnomAD 8-142875357-GC-G, CADD 0.33
- S17R (p.Ser17Arg), rs1816903838, gnomAD 8-142875357-G-T, CADD 2.56
- S17I (p.Ser17Ile), gnomAD 8-142875358-C-A, CADD 0.68
- S17K (p.Ser17Lys), gnomAD 8-142875358-C-CT, CADD 0.32
- S17N (p.Ser17Asn), gnomAD 8-142875358-C-T, CADD 0.94
- S17H (p.Ser17His), rs1299931854, gnomAD 8-142875366-GCT-G, CADD 1.33
- S17G (p.Ser17Gly), gnomAD 8-142875368-T-C, CADD 4.51
- L18P (p.Leu18Pro), Ensembl rs892400238, REVEL 0.51, CADD 21.70
- L18R (p.Leu18Arg), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- Q19* (p.Gln19Ter), rs763195324, ClinGen CA372397430, ClinVar RCV000667072, ClinVar RCV001040067, CADD 32.00, Pathogenic
- Q19H (p.Gln19His), ExAC rs753228911, TOPMed rs753228911, gnomAD rs753228911
- Q19K (p.Gln19Lys), cosmic curated COSV52829, ExAC rs763195324, TOPMed rs763195324, gnomAD rs763195324, REVEL 0.18, CADD 0.21, Uncertain significance, not provided
- Q19P (p.Gln19Pro), gnomAD rs1443899084
- A21T (p.Ala21Thr), ExAC rs765826051, gnomAD rs765826051
- A21V (p.Ala21Val), NCI-TCGA Cosmic COSV9945, cosmic curated COSV99455, Variant assessed as somatic; moderate impact.
- Q22* (p.Gln22Ter), TOPMed rs1817088012, gnomAD rs1817088012, CADD 32.00
- A23T (p.Ala23Thr), TOPMed rs1487816954, REVEL 0.15, CADD 2.53
- G25D (p.Gly25Asp), NCI-TCGA Cosmic COSV5283, cosmic curated COSV52831, REVEL 0.27, CADD 22.20, Variant assessed as somatic; moderate impact.
- G25S (p.Gly25Ser), rs771206231, ClinGen CA4905727, NCI-TCGA Cosmic COSV5282, cosmic curated COSV52824, REVEL 0.13, CADD 13.80, Likely benign, not provided
- G25G (p.Gly25Gly), gnomAD 8-142875375-A-C, CADD 0.15
- G25V (p.Gly25Val), rs1202367234, gnomAD 8-142875375-AC-A, CADD 0.33
- G25C (p.Gly25Cys), gnomAD 8-142875377-C-A, CADD 4.78
- G25R (p.Gly25Arg), rs1267126864, gnomAD 8-142875377-C-G, CADD 5.36
- T26K (p.Thr26Lys), 1000Genomes rs139569725, ESP rs139569725, ExAC rs139569725, TOPMed rs139569725, REVEL 0.17, CADD 20.80, Uncertain significance
- T26M (p.Thr26Met), rs139569725, ClinGen CA4905724, cosmic curated COSV52825, ClinVar RCV000487967, REVEL 0.21, CADD 21.30, Uncertain significance, Deficiency of steroid 11-beta-monooxygenase; Glucocorticoid-remediable aldostero
- T26R (p.Thr26Arg), 1000Genomes rs139569725, ESP rs139569725, ExAC rs139569725, TOPMed rs139569725, REVEL 0.23, CADD 16.80, Uncertain significance
- R27* (p.Arg27Ter), gnomAD rs1817087391, CADD 32.00
- R27I (p.Arg27Ile), ExAC rs768585386, TOPMed rs768585386, gnomAD rs768585386, REVEL 0.28, CADD 19.30
- R27T (p.Arg27Thr), ExAC rs768585386, TOPMed rs768585386, gnomAD rs768585386, REVEL 0.10, CADD 6.06
- A28D (p.Ala28Asp), ExAC rs749211518, gnomAD rs749211518, REVEL 0.27, AlphaMissense 0.13
- A28T (p.Ala28Thr), rs1413243201, NCI-TCGA Cosmic COSV5282, cosmic curated COSV52825, TOPMed rs1413243201, REVEL 0.27, CADD 20.50, Variant assessed as somatic; moderate impact.
- A28V (p.Ala28Val), rs749211518, NCI-TCGA Cosmic COSV5282, cosmic curated COSV52826, ExAC rs749211518, AlphaMissense 0.13, MetaLR 0.63, Variant assessed as somatic; moderate impact.
- A29T (p.Ala29Thr), rs144224988, cosmic curated COSV52825, 1000Genomes rs144224988, ESP rs144224988, REVEL 0.13, CADD 0.01, Uncertain significance, Deficiency of steroid 11-beta-monooxygenase
- A29V (p.Ala29Val), cosmic curated COSV52824, ExAC rs756034651, gnomAD rs756034651, REVEL 0.12, CADD 4.18
- A29A (p.Ala29Ala), rs61752791, gnomAD 8-142875372-T-A, CADD 0.06
- A29E (p.Ala29Glu), gnomAD 8-142875373-G-T, CADD 1.60
- R30Q (p.Arg30Gln), rs201103987, ClinGen CA4905716, cosmic curated COSV52830, ClinVar RCV000945460, REVEL 0.14, CADD 0.76, Likely benign, not provided; Deficiency of steroid 11-beta-monooxygenase; Glucocorticoid-remedi
- R30W (p.Arg30Trp), cosmic curated COSV52830, ESP rs140274628, ExAC rs140274628, TOPMed rs140274628, REVEL 0.31, CADD 11.00, Uncertain significance, not provided
- V31D (p.Val31Asp), NCI-TCGA Cosmic COSV9945, cosmic curated COSV99455, Variant assessed as somatic; moderate impact.
- V31F (p.Val31Phe), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- V31I (p.Val31Ile), TOPMed rs1402877642, gnomAD rs1402877642, REVEL 0.08, CADD 8.98
- V31L (p.Val31Leu), TOPMed rs1402877642, gnomAD rs1402877642, REVEL 0.11, CADD 4.33
- P32A (p.Pro32Ala), ExAC rs752773985, TOPMed rs752773985, gnomAD rs752773985, REVEL 0.27, CADD 7.10
- P32H (p.Pro32His), Ensembl rs2130286722
- P32S (p.Pro32Ser), ExAC rs752773985, TOPMed rs752773985, gnomAD rs752773985, REVEL 0.23, CADD 2.90
- P32T (p.Pro32Thr), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- R33K (p.Arg33Lys), TOPMed rs1817086378, REVEL 0.10, CADD 1.38
- T34I (p.Thr34Ile), gnomAD rs1817086310, REVEL 0.15, CADD 11.60
- T34T (p.Thr34Thr), rs769431602, gnomAD 8-142875339-G-A, CADD 0.75
- T34A (p.Thr34Ala), rs780289850, gnomAD 8-142875341-T-C, CADD 2.81
- T34K (p.Thr34Lys), gnomAD 8-142875364-G-T, CADD 0.31
- T34P (p.Thr34Pro), rs1816904250, gnomAD 8-142875365-T-G, CADD 1.92
- V35A (p.Val35Ala), rs201951316, ClinGen CA4905712, ClinVar RCV000304435, ClinVar RCV000361436, REVEL 0.15, CADD 18.00, Conflicting interpretations, not provided; Glucocorticoid-remediable aldosteronism; Deficiency of steroid 11
- V35L (p.Val35Leu), Ensembl rs2130286669
- L36Q (p.Leu36Gln), ExAC rs755448048, TOPMed rs755448048, gnomAD rs755448048, REVEL 0.12, CADD 14.50, Uncertain significance, Inborn genetic diseases
- L36R (p.Leu36Arg), rs755448048, ClinGen CA372397334, ClinVar RCV001158809, ClinVar RCV001163731, REVEL 0.13, CADD 11.20, Uncertain significance, Glucocorticoid-remediable aldosteronism; Deficiency of steroid 11-beta-monooxyge
- L36L (p.Leu36Leu), gnomAD 8-142875345-C-A, CADD 9.42
- L36M (p.Leu36Met), gnomAD 8-142875347-G-T, CADD 9.78
- P37S (p.Pro37Ser), ESP rs369941128, TOPMed rs369941128, gnomAD rs369941128, REVEL 0.45, CADD 22.40, Uncertain significance, Glucocorticoid-remediable aldosteronism; Deficiency of steroid 11-beta-monooxyge
- P37P (p.Pro37Pro), gnomAD 8-142875354-G-A, CADD 0.13
- P37H (p.Pro37His), gnomAD 8-142875355-G-T, CADD 0.15
- P37L (p.Pro37Leu), rs1369120151, gnomAD 8-142875355-G-A, CADD 0.18
- P37T (p.Pro37Thr), gnomAD 8-142875356-G-T, CADD 0.97
- F38I (p.Phe38Ile), ExAC rs754316010, gnomAD rs754316010, REVEL 0.67, CADD 24.30, Uncertain significance, Glucocorticoid-remediable aldosteronism; Deficiency of steroid 11-beta-monooxyge
- E39K (p.Glu39Lys), 1000Genomes rs1817085799, TOPMed rs1817085799, REVEL 0.18, CADD 18.10
- E39Q (p.Glu39Gln), 1000Genomes rs1817085799, TOPMed rs1817085799, REVEL 0.23, CADD 20.80
- E39E (p.Glu39Glu), rs766555028, gnomAD 8-142875369-C-T, CADD 2.44
- E39D (p.Glu39Asp), gnomAD 8-142875369-C-A, CADD 3.32
- E39G (p.Glu39Gly), gnomAD 8-142875370-T-C, CADD 3.71
- E39* (p.Glu39Ter), gnomAD 8-142875371-C-A, CADD 3.59
- E39R (p.Glu39Arg), gnomAD 8-142875371-C-CT, CADD 1.22
- A40D (p.Ala40Asp), NCI-TCGA Cosmic COSV5282, NCI-TCGA Cosmic COSV9945, cosmic curated COSV99455, Variant assessed as somatic; moderate impact.
- A40V (p.Ala40Val), rs61752795, gnomAD 8-142875325-G-A, CADD 2.69
- A40T (p.Ala40Thr), rs1816902550, gnomAD 8-142875326-C-T, CADD 3.63
- A40S (p.Ala40Ser), rs1816902550, gnomAD 8-142875326-C-A, CADD 2.90
- M41I (p.Met41Ile), gnomAD 8-142875330-C-A, CADD 1.47
- M41K (p.Met41Lys), gnomAD 8-142875331-A-T, CADD 0.52
- M41T (p.Met41Thr), rs780845350, gnomAD 8-142875331-A-G, CADD 3.43
- M41V (p.Met41Val), rs61752794, gnomAD 8-142875332-T-C, CADD 0.14
- P42A (p.Pro42Ala), rs104894069, ClinGen CA372397298, ClinVar RCV002033028, ESP rs104894069, AlphaMissense 0.52, MetaLR 0.90, Likely pathogenic, not provided
- P42L (p.Pro42Leu), rs193922538, ClinGen CA213661, ClinVar RCV000029643, ClinVar RCV001852593, REVEL 0.59, CADD 23.80, Likely pathogenic, Deficiency of steroid 11-beta-monooxygenase; Glucocorticoid-remediable aldostero
- P42R (p.Pro42Arg), rs193922538, ClinGen CA372397296, ClinVar RCV003046345, REVEL 0.60, CADD 23.60, Likely pathogenic, not provided
- P42S (p.Pro42Ser), rs104894069, ClinGen CA213660, ClinVar RCV000001238, ClinVar RCV000029642, REVEL 0.77, AlphaMissense 0.52, Pathogenic/Likely pathogenic, Glucocorticoid-remediable aldosteronism; Deficiency of steroid 11-beta-monooxyge
- P42T (p.Pro42Thr), rs104894069, ClinGen CA372397297, ClinVar RCV002048247, ESP rs104894069, AlphaMissense 0.52, MetaLR 0.90, Likely pathogenic, not provided
- R43Q (p.Arg43Gln), rs4534, ClinGen CA4905708, cosmic curated COSV52824, ClinVar RCV000339466, REVEL 0.14, CADD 0.09, Benign/Likely benign, not specified; not provided; Glucocorticoid-remediable aldosteronism
- R43W (p.Arg43Trp), rs369213890, cosmic curated COSV10462, ESP rs369213890, ExAC rs369213890, REVEL 0.21, CADD 21.90, Uncertain significance, Glucocorticoid-remediable aldosteronism; Deficiency of steroid 11-beta-monooxyge
- R43S (p.Arg43Ser), gnomAD 8-142875342-C-A, CADD 8.72
- R43K (p.Arg43Lys), rs749627330, gnomAD 8-142875343-C-T, CADD 5.60
- R44C (p.Arg44Cys), rs761472886, NCI-TCGA Cosmic COSV9945, cosmic curated COSV99455, ExAC rs761472886, REVEL 0.08, CADD 7.59, Variant assessed as somatic; moderate impact.
- R44H (p.Arg44His), rs200952801, cosmic curated COSV52825, 1000Genomes rs200952801, ESP rs200952801, REVEL 0.07, CADD 0.26, Uncertain significance, Inborn genetic diseases
- P45S (p.Pro45Ser), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- P45L (p.Pro45Leu), rs1290274077, gnomAD 8-142875322-G-A, CADD 3.82
- G46C (p.Gly46Cys), NCI-TCGA Cosmic COSV5282, Variant assessed as somatic; moderate impact.
- G46S (p.Gly46Ser), NCI-TCGA Cosmic COSV5282, cosmic curated COSV52824, gnomAD rs1817085014, REVEL 0.04, CADD 6.41, Variant assessed as somatic; moderate impact.
- G46G (p.Gly46Gly), rs56715454, gnomAD 8-142875360-T-C, CADD 0.24
- G46E (p.Gly46Glu), gnomAD 8-142875361-C-T, CADD 4.25
- G46R (p.Gly46Arg), gnomAD 8-142875362-C-T, CADD 0.62
- N47K (p.Asn47Lys), Ensembl rs1817084878, REVEL 0.14, CADD 18.60
- W49* (p.Trp49Ter), rs2488682060, ClinGen CA372397256, ClinVar RCV002908920, CADD 36.00, Pathogenic
- L50L (p.Leu50Leu), gnomAD 8-142875336-A-G, CADD 1.67
- L50P (p.Leu50Pro), rs1816902981, gnomAD 8-142875337-A-G, CADD 10.10
- L50I (p.Leu50Ile), gnomAD 8-142875338-G-T, CADD 6.62
- R51K (p.Arg51Lys), ExAC rs775358429, TOPMed rs775358429, gnomAD rs775358429, REVEL 0.03, CADD 6.57
- R51S (p.Arg51Ser), ExAC rs769684367, gnomAD rs769684367, REVEL 0.22, CADD 22.70
- R51T (p.Arg51Thr), ExAC rs775358429, TOPMed rs775358429, gnomAD rs775358429, REVEL 0.26, CADD 20.60
- L52V (p.Leu52Val), ExAC rs745709636, gnomAD rs745709636, REVEL 0.13, CADD 0.66
- L53Q (p.Leu53Gln), NCI-TCGA Cosmic COSV5283, cosmic curated COSV52830, Ensembl rs1586561962, Variant assessed as somatic; moderate impact.
- Q54* (p.Gln54Ter), Ensembl rs2130286396
- I55N (p.Ile55Asn), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- I55I (p.Ile55Ile), rs769070161, gnomAD 8-142875351-G-T, CADD 0.38
- I55T (p.Ile55Thr), rs774884519, gnomAD 8-142875352-A-G, CADD 6.12
- I55V (p.Ile55Val), rs61752793, gnomAD 8-142875353-T-C, CADD 0.36
- W56* (p.Trp56Ter), rs1383321200, ClinGen CA372397212, ClinVar RCV000672260, TOPMed rs1383321200, AlphaMissense 0.50, MetaLR 0.69, Likely pathogenic
- W56C (p.Trp56Cys), rs1383321200, NCI-TCGA Cosmic COSV9945, cosmic curated COSV99455, TOPMed rs1383321200, REVEL 0.46, AlphaMissense 0.50, Likely pathogenic
- W56S (p.Trp56Ser), rs778994889, ExAC rs778994889, gnomAD rs778994889, AlphaMissense 0.38, MetaLR 0.68, Variant assessed as somatic; moderate impact.
- R57M (p.Arg57Met), NCI-TCGA Cosmic COSV9945, Variant assessed as somatic; moderate impact.
- R57W (p.Arg57Trp), Ensembl rs2130286350
- E58A (p.Glu58Ala), ExAC rs754364294, gnomAD rs754364294, REVEL 0.10, CADD 18.90
- E58K (p.Glu58Lys), ExAC rs755069041, gnomAD rs755069041, REVEL 0.24, CADD 19.10, Uncertain significance, Glucocorticoid-remediable aldosteronism; Deficiency of steroid 11-beta-monooxyge
- Q59E (p.Gln59Glu), ExAC rs766911727, gnomAD rs766911727
- Q59H (p.Gln59His), ExAC rs756448189, gnomAD rs756448189, REVEL 0.33, CADD 17.10
- Q59L (p.Gln59Leu), TOPMed rs1439628323
- Y61C (p.Tyr61Cys), rs1410691484, NCI-TCGA Cosmic COSV5282, cosmic curated COSV52825, TOPMed rs1410691484, REVEL 0.28, CADD 15.70, Variant assessed as somatic; moderate impact.
- Y61H (p.Tyr61His), TOPMed rs1158682185, gnomAD rs1158682185, REVEL 0.12, CADD 5.84, Uncertain significance, Glucocorticoid-remediable aldosteronism; Deficiency of steroid 11-beta-monooxyge
- E62D (p.Glu62Asp), NCI-TCGA Cosmic COSV5282, cosmic curated COSV52828, REVEL 0.04, CADD 7.25, Variant assessed as somatic; moderate impact.
- D63H (p.Asp63His), rs5282, ClinGen CA4905689, cosmic curated COSV52829, ClinVar RCV000668553, REVEL 0.06, CADD 5.86, Conflicting interpretations, Congenital adrenal hyperplasia; not provided
- D63Y (p.Asp63Tyr), rs751135858, gnomAD 8-142875329-C-A, CADD 7.92
- D63N (p.Asp63Asn), rs751135858, gnomAD 8-142875329-C-T, CADD 6.92
- L64P (p.Leu64Pro), gnomAD rs1245981952, REVEL 0.41, CADD 23.70, Uncertain significance, Deficiency of steroid 11-beta-monooxygenase
- L64Q (p.Leu64Gln), NCI-TCGA Cosmic COSV9945, cosmic curated COSV99455, Variant assessed as somatic; moderate impact.
- L66M (p.Leu66Met), ExAC rs763658052, TOPMed rs763658052, gnomAD rs763658052, REVEL 0.35, CADD 22.50
- L66Q (p.Leu66Gln), gnomAD rs1315333704
- E67K (p.Glu67Lys), rs762414385, ClinGen CA4905686, cosmic curated COSV10642, ClinVar RCV002792799, REVEL 0.36, CADD 18.70, Uncertain significance, Inborn genetic diseases
- V68A (p.Val68Ala), NCI-TCGA Cosmic COSV5282, cosmic curated COSV52828, Variant assessed as somatic; moderate impact.
- V68I (p.Val68Ile), ExAC rs769810247, gnomAD rs769810247, REVEL 0.14, CADD 5.25
- H69Q (p.His69Gln), rs776502555, ClinGen CA4905681, ClinVar RCV002674790, ClinVar RCV004750858, REVEL 0.20, CADD 0.32, Uncertain significance, Inborn genetic diseases
- H69R (p.His69Arg), rs747287245, ClinGen CA187467710, cosmic curated COSV10734, ClinVar RCV001163729, REVEL 0.45, CADD 22.30, Uncertain significance, Glucocorticoid-remediable aldosteronism; Deficiency of steroid 11-beta-monooxyge
- T71N (p.Thr71Asn), TOPMed rs1425271405, gnomAD rs1425271405, REVEL 0.07, CADD 9.27
- F72Y (p.Phe72Tyr), TOPMed rs1817081484, REVEL 0.60, CADD 24.20, Uncertain significance, Glucocorticoid-remediable aldosteronism; Deficiency of steroid 11-beta-monooxyge
- Q73* (p.Gln73Ter), rs1554653675, ClinGen CA372397102, ClinVar RCV000674113, ClinVar RCV001233426, Pathogenic
- Q73P (p.Gln73Pro), ESP rs371662064, ExAC rs371662064, TOPMed rs371662064, gnomAD rs371662064, Uncertain significance
- Q73R (p.Gln73Arg), rs371662064, ClinGen CA4905679, ClinVar RCV001163727, ClinVar RCV001163728, REVEL 0.08, CADD 17.00, Uncertain significance, Glucocorticoid-remediable aldosteronism; Deficiency of steroid 11-beta-monooxyge
- E74D (p.Glu74Asp), 1000Genomes rs200096159, ExAC rs200096159, TOPMed rs200096159, gnomAD rs200096159, REVEL 0.26, CADD 14.10, Likely benign
- E74K (p.Glu74Lys), NCI-TCGA Cosmic COSV5282, cosmic curated COSV52827, Variant assessed as somatic; moderate impact.
- L75P (p.Leu75Pro), TOPMed rs1218458250
- G76R (p.Gly76Arg), NCI-TCGA Cosmic COSV9945, cosmic curated COSV99454, REVEL 0.70, CADD 24.00, Variant assessed as somatic; moderate impact.
- P77A (p.Pro77Ala), ExAC rs750931191, TOPMed rs750931191, gnomAD rs750931191
- P77S (p.Pro77Ser), ExAC rs750931191, TOPMed rs750931191, gnomAD rs750931191, REVEL 0.51, CADD 23.90
- P77T (p.Pro77Thr), ExAC rs750931191, TOPMed rs750931191, gnomAD rs750931191, REVEL 0.59, CADD 23.70
- F79I (p.Phe79Ile), rs1489638195, ClinGen CA372397068, ClinVar RCV000665385, ClinVar RCV002271551, REVEL 0.60, CADD 25.00, Pathogenic/Likely pathogenic, Differences in sex development; Congenital adrenal hyperplasia; Deficiency of st
Public CYP11B1 analysis runs
- CYP11B1 analysis run — CYP11B1 (1,063 variants) — completed 2026-08-21